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A B ST R AC T 
 
 
Oral manifestations are present both in Cushing's syndrome and in adrenal 
insufficiency. Possible oro-dental pathology in patients with Cushing's 
syndrome include jawbone loss, tooth loss, and periodontal diseases. 
Professional societies did not include Cushing's syndrome as being part of 
systemic diseases associated with loss of periodontal supporting tissues. The 
comorbidities of Cushing's syndrome such as obesity, osteoporosis, and 
diabetes are conditions that influence periodontal attachment apparatus. In 
patients with adrenal primary insufficiency, the most specific sign is the 
melanic pigmentation of the skin and mucosal surfaces due to increments of 
corticotropin and pro-opiomelanocortin peptide levels that occur as a result 
of decreased cortisol feedback. The oral mucosa develops black plaques that 
can also be present on the gums, palate, tongue, and lips. The pallor may 
occur in patients with adrenocortical insufficiency secondary to 
corticotropin deficiency. Patients with primary adrenal insufficiency need to 
increase their glucocorticoid doses during physical activity, intercurrent 
illnesses, surgery, and medical procedures. Current evidence indicates that 
routine, nonsurgical, or minor surgical procedures do not need supplemental 
glucocorticoids in diagnosed patients who are in a stable condition. 
However, for major oral surgery, glucocorticoid supplementation is 
necessary for the surgery day and for at least one postoperative day.   
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Periodontal diseases, also known as gum diseases, are 
being detected more frequently in patients undergoing 
routine dental control. This type of pathology is linked to 
several metabolic imbalances but can also originate from 
hormone level fluctuations. Understanding the 
connection between glucocorticoid levels and several 
characteristic manifestations of oro-dental pathologies 
can help dentists develop better therapeutic protocols. 
The endocrinologist and the dentist need to be familiar 
with the oral manifestations of endocrine conditions and 
must have good communication to maintain patient oral 
health in Cushing's syndrome and to prevent a possible 
adrenal crisis in the case of major oral surgery in patients 
with adrenal insufficiency. 
Discussions 
Cushing's syndrome  
Cushing's syndrome is a disorder characterized by 
chronic exposure to glucocorticoid excess. The etiology of 
this syndrome includes exogenous or endogenous 
hypercortisolism [1]. The exogenous (or iatrogenic) 
Cushing's syndrome is the most common cause of 
hypercortisolism and is generated by administration of 
supraphysiologic doses of steroid therapy for 
inflammatory, autoimmune, or neoplastic disorders [2]. 
The endogenous Cushing's syndrome includes 
adrenocorticotropic hormone (ACTH) dependent or ACTH 
independent forms. ACTH dependent Cushing's syndrome 
is generated by ACTH production by a pituitary adenoma 
or nonpituitary tumors and excess of corticotropin-
releasing hormone producing tumors [3]. Ectopic ACTH 
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production derives from pulmonary carcinoid tumor, 
pancreatic or thymic neuroendocrine tumors, medullar 
thyroid cancer, pheochromocytoma etc. [4]. Păun et al. 
described ectopic ACTH-dependent Cushing's syndrome 
arising from a Meckel diverticulum [5]. ACTH-dependent 
Cushing's syndrome accounts for 80 % of cases [1]. With 
a much lower frequency (15-20%), ACTH-independent 
Cushing's syndrome can by generated by adrenal unilateral 
tumors, macronodular adrenal hyperplasia, or primary 
pigmented nodular adrenal disease [1]. 
The most common signs of disease are represented by 
progressive weight gain, moon face, supraclavicular and 
dorsocervical fat pads, hirsutism or alopecia, facial 
plethora, violaceous striae, acne, depression, and mania. 
The clinical presentation is influenced by age, sex, and the 
severity and duration of hypercortisolism [1,6,7]. 
However, it should be mentioned that no signs or 
symptoms are pathognomonic. The chronic glucocorticoid 
exposure is associated with comorbidities such as obesity, 
cardiovascular diseases, hypercoagulability, impaired 
glucose tolerance or diabetes mellitus, dyslipidemia, 
osteoporosis, and increased susceptibility to infection with 
common or unusual agents [8].  
Possible oro-dental pathology in patients with 
Cushing's syndrome can include jawbone loss, tooth loss, 
and periodontal diseases. The jawbone supports the teeth; 
when bone becomes less dense the tooth mobility is 
increased [9]. Periodontal disease is a set of inflammatory 
conditions affecting the tissues surrounding the teeth. In 
2017, the “American Academy of Periodontology (AAP) 
and the European Federation of Periodontology (EFP)” 
recommended a classification for periodontal and per-
implant disease and conditions. Periodontal disease and 
conditions comprise three major categories [10]:  
“1. Periodontal health and gingival diseases: periodontal 
and gingival health, gingivitis caused by biofilm, 
gingivitis not caused by biofilm. 
2. Periodontitis: necrotizing diseases, periodontitis, 
periodontitis as a manifestation of systemic disease.  
3. Other conditions affecting the periodontium: systemic 
diseases affecting the periodontal supporting tissues, 
periodontal abscess, or periodontal and endodontic 
lesions, mucogingival deformities and conditions, 
traumatic occlusal forces, tooth, and prosthesis related 
factor.” 
The peri-implant disease and conditions include peri-
implant health, peri-implant mucositis, peri-implantitis and 
peri-implant soft- and hard-tissue deficiencies [10]. 
The proceedings of the workshop conducted by AAP 
and EFP did not include Cushing's syndrome among the 
systemic diseases associated with loss of periodontal 
supporting tissues. Comorbidities of Cushing's syndrome 
such as obesity, osteoporosis, and diabetes are mentioned 
among the conditions that affect periodontal attachment 
apparatus [11]. In Cushing's syndrome, the prevalence of 
obesity varies between 70% and 95%, that of osteoporosis 
between 50%-80%, and that of diabetes mellitus between 
20%-50% [1,12]. The possible mechanisms by which 
obesity increases periodontitis, periodontal disease 
progression, and loss of periodontal attachment risk 
include immune response and increased production of 
proinflammatory cytokines. A systematic review regarding 
the association between obesity and periodontitis was 
published in 2010 in the Journal of Periodontology by 
Chaffee and Weston. After systematic analysis of 
databases, the authors conclude that obesity increases 
susceptibility to infection and “obesity is a risk factor for 
periodontal disease or that periodontitis might increase the 
risk of weight gain” [13]. The likelihood of periodontitis in 
obese patients varies between 50% to 80% compared with 
normal-weight subjects, and the risk is higher among obese 
women compared with obese men [13,14]. The response to 
periodontal treatment does not differ for obese patients 
versus normal-weight subjects [15].  
Osteoporosis is associated with a higher prevalence of 
alveolar bone loss but the association with periodontitis is 
not clear [11]. Beetaka and coworkers published in 2013 in 
Dental Research Journal a study about the oral health of 
patients under long-term corticosteroid therapy. 100 
patients who received corticosteroid therapy for a 
minimum of 3-months duration and 100 healthy subjects 
were included in the study. The results showed that 
“Patients on steroids exhibited significantly higher levels 
of candidiasis and clinical attachment loss of the 
periodontal ligament, probing pocket depth. Bone density 
was significantly lower in the study group than that in the 
control group. Random blood glucose was significantly 
higher and significant lower levels of calcium were 
observed in patients on steroids” [16].  
 Oral health in patients on inhaled corticoid therapy 
was investigated in 30 patients with chronic obstructive 
pulmonary disease by Komerik et al. Results were 
compared with those of 30 healthy subjects. The study 
revealed that in patients on steroid treatment, bone density 
of the mandible was lower than in the control group, and 
the patients had more missing teeth [17]. Bisphosphonates 
are the first line options for treatment of osteoporosis but 
do not directly address the decreased bone characteristic of 
the glucocorticoid-induced bone disease [18]. Treatment 
with bisphosphonates can generate osteonecrosis of the 
jaw, typically diagnosed after an invasive procedure, and 
associated with poor dental hygiene and infection. Other 
risk factors for bisphosphonates-associated osteonecrosis 
of the jaw are cancer and anti-cancer therapy, duration of 
exposure to therapy, glucocorticoids, pre-existing dental or 
periodontal disease, tobacco and alcohol abuse, etc. 
[18,19]. Before prescribing bisphosphonates, the 
“American Society for Bone and Mineral Research” 
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recommends communication between physicians and 
dentists, informing patients about the benefits and risks of 
bisphosphonates, including the risk for developing jaw 
osteonecrosis and the signs and symptoms of jaw 
osteonecrosis (pain, swelling, suppuration, soft tissue 
ulceration, intra-or extraoral sinus tracks, loosening of 
teeth). Patients in treatment with bisphosphonates should 
be encouraged to maintain good oral hygiene and to have 
regular dental visits and to report any oral problems [19].  
There is information on potential pathways which 
support the association between diabetes mellitus and 
periodontitis. The presence of hyperglycemia in gingival 
crevicular fluid can generate the growth of certain bacterial 
species in the subgingival environment which may increase 
susceptibility to periodontitis. The hyperinflammatory 
response to bacterial challenge can generate 
hyperinflammatory response of monocytes, increased 
release of proinflammatory cytokines, and oxidative stress 
reactions [11,20]. In patients with type 1 diabetes mellitus 
there is evidence that monocytes have a 
hyperinflammatory phenotype and cells are responding to 
periodontal bacteria, producing higher levels of interleukin 
1β, prostaglandin E2, and tumor necrosis factor alpha, 
suggesting that this phenomenon may be involved in the 
pathogenesis of periodontitis in diabetes [21,22]. 
Increasing nonenzymatic protein glycation characteristic 
of diabetes mellitus can generate the advanced glycation 
end products (AGEs). Several studies have shown that 
AGEs contribute to the diabetic complications and, 
regarding the periodontal tissue, AGEs contribute to 
increase of alveolar loss in diabetic mice [23]. Diabetes is 
a redox imbalance disease [24-26]. The oxidative stress is 
involved in the pathogenesis of diabetes complications and 
there is evidence showing increased local and systemic 
alterations in the redox balance of periodontitis [27].   
Diagnostic of Cushing's syndrome. In 2008, the 
Endocrine Society Guidelines recommended exclusion of 
exogenous doses of glucocorticoid therapy before 
conducting biochemical testing. Testing for Cushing's 
syndrome is recommended in the following situations: 
patients with unusual features for age, with multiple and 
progressive features predictive of the syndrome, adrenal 
incidentaloma, or children with decreased height and 
increased weight. For the initial testing, the Endocrine 
Society guidelines recommend urine free cortisol, late–
night salivary cortisol, 1-mg overnight dexamethasone 
suppression test, and long low dose dexamethasone 
suppression test (2 mg). In individuals with abnormal test 
results, the following investigations are recommended: 
random serum cortisol or ACTH levels, urinary 17-
ketosteroids, pituitary and adrenal imaging, and 8 mg 
dexamethasone suppression test [28]. 
Management of Cushing's syndrome. The Clinical 
Practice Guidelines of the Endocrine Society published in 
2015 in “The Journal of Clinical Endocrinology & 
Metabolism”, recommend that effective treatment should 
include normalization of cortisol levels or action. 
“Surgical resection of the causal lesion(s) is generally the 
first-line approach. The choice of second-line treatments, 
including medication, bilateral adrenalectomy, and 
radiation therapy (for corticotrope hormone), must be 
individualized to each patient” [29]. Treatment of 
comorbidities is important to reduce mortality. 
Management of exogenous Cushing's syndrome involves: 
dose and duration of glucocorticoid therapy should be kept 
as low as possible, pulse glucocorticoid therapy should be 
used only when absolutely indicated, use of highly potent 
and long-acting glucocorticoid should be restricted to acute 
setting only, and short-acting glucocorticoid is preferred 
for long-term treatment [30]. 
Adrenocortical insufficiency  
Adrenal insufficiency can be generated by destruction 
of adrenal cortex (primary adrenocortical insufficiency) or 
can be secondary to pituitary or hypothalamic diseases. 
The condition can manifest as a chronic or acute form 
[31,32]. Primary adrenal insufficiency is a relatively rare 
disease. Its etiology includes autoimmune adrenalitis, 
infectious diseases (tuberculosis, fungal, viral), neoplastic 
diseases, adrenal hemorrhage or thrombosis, drug, 
infiltration, and neonatal or genetic conditions. Secondary 
adrenocortical insufficiency can be generated by pituitary 
or metastatic tumors, craniopharyngioma, pituitary surgery 
or irradiation, infiltration, empty sella syndrome, Sheehan 
syndrome, lesions of the pituitary stalk, hypothalamic 
tumors, and exogenous corticosteroids [33]. In primary 
adrenal insufficiency there is a deficiency of the 
glucocorticoid and mineralocorticoid hormones. Cortisol 
deficiency manifests as fatigue, anorexia, nausea, weight 
loss, diminished resistance to infection, and 
hyperpigmentation as a consequence of cessation of 
inhibition at pituitary level with increments of ACTH and 
melanocyte stimulating hormone. Aldosterone deficiency 
generates sodium and liquid depletion, increased diuresis, 
and secondary hypotension and dehydration. In secondary 
adrenocortical insufficiency, the mineralocorticoid 
function is preserved [34]. 
Oro-dental pathology in patients with adrenal 
insufficiency. The most specific sign of primary adrenal 
insufficiency is the melanic pigmentation of the skin and 
mucosal surfaces as a consequence of increments of 
corticotropin and pro-opiomelanocortin peptide levels that 
result from decreased cortisol feedback. The oral mucosa 
develops black plaques that can be also present on the 
gums, palate, tongue and lips. Pallor may occur in patients 
with secondary adrenocortical insufficiency secondary to 
corticotropin deficiency [35,36]. 
Diagnostic of adrenal insufficiency. Serum cortisol is 
a test used in the screening and diagnosis of adrenal 
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insufficiency and can be measured in early morning 
between 08.00 and 09.00 h. Betterle Cet al. mention that 
“Hormonal pattern of morning plasma cortisol 
concentrations of less than 3 μg/dl (83 nmol/liter) are 
indicative of clinical adrenal insufficiency whereas 
concentrations of more than 19 μg/dl (525 nmol/liter) rule 
out the disorder“ [33]. Measurement of serum cortisol may 
represent the first laboratory test in patients evaluated for 
hypothalamic, pituitary, and adrenal insufficiency [37]. 
Determining values of plasma ACTH is used to 
differentiate between primary and secondary adrenal 
insufficiency. The Clinical Guidelines Subcommittee of 
the Endocrine Society recommends confirmatory testing 
with corticotropin for diagnosis of primary adrenal 
insufficiency. The guidelines suggest the standard dose of 
250 ug for adults, 15 μg/kg for infants and 125 μg for 
children under 2 years of age, in intravenous 
administration. The low dose (1μg) corticotropin test is 
recommended when the substance itself is in short supply. 
To assess the presence of mineralocorticoid deficiency, the 
simultaneous measurement of plasma renin and 
aldosterone is recommended. After an endocrinological 
diagnosis has been established by hormonal testing, the 
etiology of the disease should be determined [38].   
Management of adrenal insufficiency. The Clinical 
Guidelines of the Endocrine Society published in 2016 
recommend glucocorticoid and mineralocorticoid 
replacement in all patients with confirmed adrenal 
insufficiency. In adults, glucocorticoid replacement can be 
achieved by administering hydrocortisone 15-25 mg/day or 
cortisone acetate 20-35 mg/day in two or three divided 
doses administered via oral route; the highest dose should 
be given in the morning. In patients with reduced 
compliance an alternative is prednisolone 3-5 mg once or 
twice per day administrated orally. In children, 
glucocorticoid replacement can be achieved by oral intake 
of hydrocortisone in three or four doses, with total starting 
dose of 8 mg/m2 body surface area. It is recommended to 
monitor glucocorticoid therapy by clinical assessment. 
Patients with primary adrenal insufficiency need to 
increase glucocorticoid doses during physical activity, 
intercurrent illnesses, surgery, and medical procedures. In 
adults, mineralocorticoid replacement can be achieved by 
administering fludrocortisones with a starting dose of 50-
100 μg/day without restricted salt intake. In children, the 
starting dose is of 100 μg/day with supplements of sodium 
chloride in the newborn up to the age of 12 months. 
Dehydroepiandrosterone replacement may be 
recommended in women with low libido, depressive 
symptoms, and asthenia which has not been optimized by 
glucocorticoid and mineralocorticoid treatment. In the 
absence of a beneficial effect of therapy after 6 months, the 
dehydroepiandrosterone should be discontinued [38,39].  
The management of adrenal insufficiency secondary to 
hypothalamic-pituitary failure conventionally is based on 
the long-term replacement of hydrocortisone (20 mg in the 
morning and 10 mg in the evening); the mineralocorticoid 
replacement is not required in patients with secondary 
adrenal insufficiency [40]. Education of the patient is 
essential for the management of this condition. Patients 
should be instructed to increase the dosage of 
glucocorticoids during intercurrent illness, fever, and 
stress, and promptly identify suggestive signs and 
symptoms of acute adrenal crisis is especially important.  
The acute adrenal crisis is an emergency that requires 
prompt recognition and therapy. Symptoms of an acute 
adrenal crisis are major impairment of general health, 
hypotension, nausea, vomiting, abdominal pain, and 
impaired cognitive function. Treatment of patients with 
possible acute adrenal crisis must be initiated immediately 
and should not be delayed by diagnostic investigations. 
Important is intravenous administration of 100 mg 
hydrocortisone followed by 100-300 mg/day as continuous 
infusion or frequent intravenous or intramuscular boluses 
every 6 hours, isotonic saline infusion, and treatment of the 
precipitating condition [38, 39].  
Dental management of the patients with adrenal 
insufficiency. In dental practice, patients experience pain 
or stress generated by procedures, and anxiety control is 
important for the dental management of these patients [39]. 
Current evidence indicates that the routine, nonsurgical, or 
minor surgical procedures do not need supplemental 
glucocorticoids in diagnosed patients in a stable condition 
[38]. Invasive procedures increase the plasma cortisol 
levels during and after a surgery. In a review published in 
2001 in the “Journal of the American Dental Association”, 
Miller and coworkers mention that “For major oral 
surgical stress (for example, multiple extractions, 
quadrant periodontal surgery, extraction of bony 
impactions, osseous surgery, osteotomy, bone resections, 
oral cancer surgery), surgical procedures involving the 
use of general anesthetic, procedures lasting more than 
one hour, or procedures associated with significant blood 
loss, the glucocorticoid target is about 50 to 100 mg per 
day of hydrocortisone equivalent for the day of surgery and 
for at least one postoperative day“ [34]. The adrenal crisis 
related to dental treatment is rarely mentioned in the 
literature. Miller et al searched the literature from 1966 to 
2000 for information that addressed adrenal insufficiency 
and adrenal crisis in dentistry; 4 reports were identified 
over 35 years [34, 41-44]. Features in 3 reports included 
patients who had multiple extractions performed with 
administration of general anesthetic or oral infection [30]. 
The authors identified four risk factors that contribute to 
the risk of adrenal crisis during the perioperative period of 
oral surgery: magnitude of surgery, general anesthetic, 
health of the patient, and the degree of anxiety control; they 
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concluded that perioperative glucocorticoid 
supplementation “can be prescribed in a more rationale 
manner than is currently the case“ [34, 45]. 
Highlights 
✓ Oro-dental pathology is linked to both glucocorticoid 
excess and deficit. 
✓ Identifying the specific periodontal symptoms 
associated with either Cushing's syndrome or 
adrenocortical insufficiency is essential for good 
dental management in these particular patients. 
Conclusions 
Oral manifestations are present in the case of 
glucocorticoid excess but also in the case of glucocorticoid 
deficiency. The endocrinologist and the dentist need to be 
familiar with the oral manifestations of these conditions 
and must ensure good communication to maintain patient 
oral health in Cushing's syndrome and prevent a possible 
adrenal crisis in the case of major oral surgery in patients 
with adrenal insufficiency.  
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